Clinical-Stage Biotech Builds FDA-Ready Research Infrastructure

The Challenge

Our client is a clinical-stage biotechnology company based in Research Triangle Park, North Carolina, developing novel small-molecule therapies for autoimmune disorders. With 60 researchers across computational biology, medicinal chemistry, and clinical operations, the company was approaching a critical inflection point: their lead compound was entering Phase II clinical trials, and they had just closed a $45 million Series B funding round to scale operations.

The problem was that the company's IT infrastructure had not kept pace with its scientific ambitions. The company had been founded three years earlier by researchers from Duke and UNC, and its technology stack still reflected its academic origins. Computational workloads — molecular dynamics simulations, genomic analysis, and machine learning model training — were running on a small cluster of workstations purchased at founding. Jobs that should have completed in hours were taking days. Researchers were queuing work overnight and on weekends just to keep up.

More critically, the company's data management practices did not meet the requirements of FDA 21 CFR Part 11, which governs electronic records and electronic signatures for data submitted to the FDA. Research data lacked audit trails, electronic signatures were not validated, and there was no formal data integrity framework. If the FDA requested an inspection — which was increasingly likely as the Phase II trial progressed — the company could not demonstrate compliance.

Intellectual property protection was another urgent concern. the company's research data, compound libraries, and proprietary algorithms represented the company's core value. The data was stored on network shares with minimal access controls, no data loss prevention measures, and no monitoring for unauthorized access or exfiltration. With $45 million in investor capital on the line, the board demanded immediate action to protect the company's IP portfolio.

The Solution

Layer27 designed a research computing and compliance infrastructure for A Clinical-Stage Biotech Company using our Infrastructure Pro and Private Cloud services, engineered from the ground up to meet the demanding requirements of biotech research and FDA regulatory compliance.

High-Performance Computing Infrastructure

Working with the company's computational biology team, Layer27 deployed a Private Cloud environment purpose-built for scientific computing. The infrastructure provides dedicated GPU-accelerated compute nodes for molecular dynamics simulations and machine learning workloads, high-throughput storage optimized for the large datasets common in genomic analysis, and a job scheduling system that allows researchers to submit workloads and monitor progress without managing infrastructure.

The result was a 10x increase in available compute capacity. Simulations that previously took three days now complete in under eight hours. Researchers spend their time on science instead of waiting for compute resources or managing hardware. The environment is fully managed under Infrastructure Pro, with Layer27 handling capacity planning, performance tuning, and hardware lifecycle management.

FDA 21 CFR Part 11 Compliance

Layer27's Compliance team worked alongside the company's quality assurance group to implement a validated computing environment that meets FDA 21 CFR Part 11 requirements. This included deploying audit trail capabilities across all systems that generate or store electronic records, implementing validated electronic signature workflows with identity verification and signature manifestation, establishing computer system validation (CSV) documentation following GAMP 5 guidelines, and creating standard operating procedures for data management, system access, and change control.

Every system in the validated environment underwent installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ). Layer27 maintains the validation documentation and manages change control processes on an ongoing basis, ensuring the company remains inspection-ready at all times.

Intellectual Property Protection

Layer27's Managed Detection & Response (MDR) service monitors the company's environment 24/7 for threats targeting research data and intellectual property. Data loss prevention (DLP) policies prevent unauthorized transfer of sensitive files. Network segmentation isolates the research computing environment from corporate systems. Access to research data is governed by role-based controls with multi-factor authentication, and all access is logged and auditable.

Dark web monitoring watches for any indication that the company's data or credentials have been compromised. Endpoint detection and response agents on all workstations and laptops provide real-time threat detection, with automated containment capabilities that can isolate a compromised device in seconds.

The Results

Within four months of engaging Layer27, A Clinical-Stage Biotech Company achieved full FDA 21 CFR Part 11 compliance and passed an internal mock FDA inspection conducted by a former FDA auditor. The validated computing environment is maintained in a state of continuous compliance, with Layer27 managing all change control and revalidation activities.

The 10x increase in compute capacity accelerated the company's research timeline measurably. The computational biology team completed a compound screening analysis in two weeks that was originally projected to take three months, contributing directly to the identification of a backup compound that strengthened the clinical pipeline.

The company has experienced zero intellectual property incidents since deployment. The board and investors have expressed confidence in the security posture, and the infrastructure has been cited as a strength in due diligence processes with potential pharmaceutical partners.

"As scientists, we want to focus on developing therapies, not managing servers. Layer27 built us a research computing environment that performs at the level we need, meets every FDA requirement, and protects the IP that our investors are counting on. Their Infrastructure Pro team understands the unique demands of biotech — they're not just IT support, they're a strategic partner in our mission."

— CEO

Key Takeaways

• FDA 21 CFR Part 11 compliance requires purpose-built infrastructure — retrofitting consumer or general-business IT systems to meet validation requirements is costly and unreliable.
• Private Cloud provides the dedicated resources and isolation that biotech companies need for validated computing environments, without the overhead of managing physical data centers.
• IP protection in biotech requires defense in depth — MDR, DLP, network segmentation, and access controls must work together to guard against both external threats and insider risk.
• Infrastructure Pro's capacity planning ensures that compute resources scale with research demands, preventing the bottlenecks that delay scientific progress and burn investor capital.